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Cardiac resynchronization therapy (CRT) is an important device-based, non-pharmacological approach that has shown, in large randomized
trials, to improve left ventricular (LV) function and reduce both morbidity and mortality rates in selected patients affected by advanced heart
failure (HF): New York Heart Association (NYHA) functional class III–IV, reduced LV systolic function with an ejection fraction (EF)  35%,
QRS duration  120 ms, on optimal medical therapy, and who were in sinus rhythm. For the ﬁrst time, the latest ESC and AHA/ACC/HRS
Guidelines have considered atrial ﬁbrillation (AF) patients, who constitute an important subgroup of HF patients, as eligible to receive CRT.
Nevertheless, these Guidelines did not include a strategy for deﬁning differentiated approaches according to AF duration or burden. In this
review, the authors explain in which way AF may interfere with adequate CRT delivery, how to manage different AF burden, and ﬁnally
present a brief overview on the effects of CRT in AF patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Cardiac resynchronization therapy (CRT) is an important device-
based, non-pharmacological approach that has shown to improve
the outcome in selected patients with chronic heart failure (HF).
Large randomized trials have demonstrated that CRT improves
left ventricular (LV) function and reduces both morbidity and mor-
tality rates.
1–5 Until recently, CRT was indicated in patients with
advanced HF [New York Heart Association (NYHA) functional
class III–IV], reduced LV systolic function [ejection fraction (EF)
 35%], evidence of electrical dyssynchrony (QRS duration
 120 ms), receiving optimal medical therapy, and who were in
sinus rhythm (SR).
6 In the last ESC recommendations,
7 for the
ﬁrst time, atrial ﬁbrillation (AF) patients, who constitute an impor-
tant subgroup of HF patients treated with CRT,
8 have been con-
sidered as eligible to receive CRT on the condition that the
effects of underlying rhythm be neutralized by atrio-ventricular
junction (AVJ) ablation. The AHA/ACC/HRS Guidelines
9 also
favourably considered CRT in HF patients with AF, without
however emphasizing the possible need for aggressive rate
control. Also, these Guidelines remain imprecise in deﬁning differ-
entiated approaches according to the forms of AF other than per-
manent. The present review explains, in the ﬁrst instance, in which
way AF interferes with adequate CRT. Secondly, a brief overview
on the effects of CRT in AF patients is presented, followed by
some recommendations, based on current evidence, on the
most adequate approach according to patient characteristics,
emphasizing the extent of atrial arrhythmic [atrial tachycardia
(AT)/AF] burden. It is important to point out that these rec-
ommendations remain unsupported by evidence derived from ran-
domized controlled trials (RCTs), which are much needed.
10
Atrial ﬁbrillation rhythm
interferes with adequate cardiac
resynchronization therapy delivery
Atrial ﬁbrillation (whether permanent, persistent, or paroxysmal)
posesanumberofchallengesforadequateCRTdelivery.Anintrinsic,
intermediate-to-high, irregular spontaneous AF rhythm reduces the
percentage of effectively biventricular paced captured beats (BVP%).
Eveninapatient whohasnormal rateAF,phasesofeffective biventri-
cular capture alternate with phases of competing AF rhythm which
causes spontaneous, fusion, or pseudo-fusion beats (Figure 1). This
suggests that the global effective ‘CRT-dose’ may be markedly
reduced compared with atrial-synchronous rhythm with a short AV
interval(asisachievedduringSR)sincethenumberofeffectivebiven-
tricular captured beats are reduced. Moreover, in AF patients, during
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determining a further reduction of paced beats precisely when
patients are most in need of having biventricular capture, thus
greatly limiting functional capacity. Another problem is the possible
negativeimpactonprognosisofusingcombinationsofnegativechron-
otropictherapytoachieveadequateratecontrol.Infact,somestudies
have‘indirectly’suggestedthattheuseofeitherdigoxinoramiodarone
in HF may increase morbidity and mortality.
4
Adequate management of AF and other atrial arrhythmias is pri-
marily based on deﬁning the AT/AF burden and how it impacts
negatively on CRT delivery.
Deﬁning atrial ﬁbrillation/atrial
tachycardia burden in heart failure
patients treated with cardiac
resynchronization therapy
Deﬁning atrial arrhythmic burden is derived from integrating clini-
cal, device-derived data, as well as instrumental ﬁndings (such as
echocardiographic measures). Any HF patient with a history of
atrial arrhythmias requires particular attention, especially in the
ﬁrst months of CRT, in order to ensure that resynchronization
be adequately delivered.
From a clinical standpoint, it is important to identify symptoms
such as palpitations, and more importantly, worsening effort dys-
pnoea which may suggest that the resynchronization effect is
reduced because of the interference of the underlying atrial
rhythm. These clinical aspects should be substantiated by instrumen-
tal echocardiographic data, which may show unchanged or further
progression of LV dysfunction expressed through increased ventri-
cular volumes and further EF reduction. Retrieving relevant infor-
mation (BVP%, duration, and numbers of ‘mode switch’ episodes,
etc.) through device monitoring (Figure 2) may complement clinical
and echocardiographic data and, thus, provide a more complete
picture on the extent of AF/AT burden in each patient. These differ-
ent aspects, all obtainable during a routine outpatient visit, allow
provision of an approximation of the effective AF/AT burden inﬂu-
encing CRT delivery. Atrial tachycardia/AF burden may be
considered high, intermediate, or low. Recently, Kamath
11 pointed
out the importance of an accurate evaluation of CRT-dose using
sophisticated 12-lead Holter monitoring, which seemed to be
more accurate than conventional device-based information.
Medical therapeutical and
device-based options for ‘rate
control’ in low atrial tachycardia/
atrial ﬁbrillation burden
Rate control strategy encompasses treatment options which effec-
tively reduce and regularize heart rate in patients who usually have
Figure 1 A patient with AF and HF treated with CRT, spontaneous irregular intrinsic beats alternate with fusion and pseudo-fusion beats,
thus markedly reducing effective CRT. As shown in the ﬁgure, this may occur even during normal rate AF.
Figure 2 Different aspects of CRT patients with AF before and
after AVJ ablation, which may be appreciated through device fea-
tures. In a 59-year-old female with permanent AF treated with a
CRT-D device, AVJ ablation yielded the following improvements:
better functional status as shown by the number of hours of
activity per day; maximization of BVP%; and improvement of
heart rate variability proﬁle.
CRT in HF patients with AF v83permanent AF or a persistent AF which cannot be readily cardio-
verted to SR. The rate control strategy embodies two aspects
which act favourably on cardiac mechanics. First, lowering heart
rate to intermediate-to-low rate allows better diastolic ﬁlling and
increases stroke volume in hearts with conserved Frank–Starling
mechanism. Secondly, the regularization of heart rate further
reinforces favourable effects on diastolic function.
12 The recourse
to rate control drugs and/or activation of device-based algorithms
is reasonable as ﬁrst-line approach when AF/AT burden is low/
intermediate.
Rate control drugs considered effective in HF patients with
depressed LV function include digoxin, amiodarone, and beta-
blockers. However, more recent ﬁndings derived from randomized
trials have suggested caution in the use of digoxin and amiodarone
in patients with HF.
13
Some device-derived features may be helpful to improve rate
controlandthusimproveCRTdelivery.Thesefeaturesincludeventri-
cular rate regularization (VRR) which consists in performing BVP,
which ‘overrides’ intrinsic rhythm, through faster ventricular-paced
depolarization allowing to reduce short cycles through retrograde
concealed penetration of the AV node.
14,15 The beneﬁts of rate
control achieved by activating VRR function is well established in
patients with chronic AF and no or only mild HF treated with a
single chamber right ventricular (RV) pacing. In these patients, VRR
has been demonstrated to confer acute haemodynamic beneﬁts,
16
to restore autonomic balance,
17 and to provide a more regular
rhythmduringexercise,
14thuspotentiallyimprovingfunctionalstatus.
Another useful feature is ‘ventricular sense response’ (also
called ‘trigger’ function) which triggers LV pacing after a premature
RV sense event is detected:
17 this option may be activated in all
CRT devices of the latest generation.
In the context of CRT, the effectiveness of such rate control and
rate regularization algorithms combined with the use of rate
control drugs has not been investigated in an RCT. Findings
derived from different large observational cohort studies on the
effects of CRT in patients with permanent AF have yielded con-
trasting results. One of these studies
18 observed that treatment
combining negative chronotropic drugs and activation of device
features (VRR and trigger mode), even if permitting 85% of biven-
tricular stimulation, did not yield signiﬁcant long-term improve-
ments in functional status, LVEF, or LV end-systolic volume
(LVESV) reduction. The ineffectiveness of this approach further
found conﬁrmation through another more extensive multicentre
European study, which reported relatively high death rate, particu-
larly occurring for worsening progressive HF in AF patients treated
with negative chronotropic drugs.
19 Quite differently, other
smaller studies have advocated
20 that to achieve good results
after CRT in terms of survival, aggressive rate control strategy is
not necessary. It is worth emphasizing, however, that when the
survival curves of the HF patients with AF treated with a combined
device-based/drug regimen are compared,
21 yearly death rate for
any cause is considered to be remarkably high, amounting to
over 14%/year in both separate cohorts of non-ablated patients
(Figure 3).
It therefore follows that in HF patients treated with CRT who
present a high or intermediate AT/AF burden, the pursuit of an
aggressive treatment strategy, such as AVJ ablation, is warranted.
Atrio-ventricular junction ablation
for the management of atrial
ﬁbrillation and atrial rhythm issues
in heart failure patients treated
with cardiac resynchronization
therapy
Atrio-ventricular junction ablation is commonly performed in
patients with symptomatic, drug-refractory, fast, permanent AF
as part of the conventional ‘ablate and pace’ strategy, and has
been shown to confer symptomatic relief.
22–24 Atrio-ventricular
junction ablation in individuals with AF treated with CRT has
mainly been conﬁned to selected patients in whom high-rate AF
or AT jeopardizes satisfactory biventricular stimulation, and in
CRT-implantable cardioverter deﬁbrillator (ICD) recipients deter-
mines inappropriate ICD interventions.
25 The problem of inap-
propriate ICD therapies during AF, constituting 30% of all ICD
interventions,
25 has an important negative impact on the quality
of life of patients and may be completely resolved after AVJ abla-
tion. However, in the context of CRT in HF patients with conco-
mitantAF,agrowingamountofevidencehasdemonstratedthatAVJ
ablation may be useful to optimize CRT delivery by eliminating the
deleterious haemodynamic effects of a competing, irregular, spon-
taneous intrinsic rhythm. The MUSTIC AF randomized trial,
26
besides being the ﬁrst randomized trial demonstrating possible
beneﬁtsofCRT in HFpatients with permanentAFand conventional
indication for CRT, also showedthatin these patients, the preferred
mode of ventricular stimulation was biventricular as opposed to RV.
The study enrolled AF patients with either slow-rate AF or those
who underwent ablation of the AV node; the effects between
pacing modes were compared using a crossover design with two
3-month periods. Although no result was found in the
Figure 3 Comparison of Kaplan–Meier analysis for freedom
from death for any cause between the Gasparini et al.
19 and
the Khadjooi et al.
20 studies. The ﬁgure is adapted from Gasparini
et al.
19 and Khadjooi et al.
20 SR, sinus rhythm; AF, atrial ﬁbrillation;
AF-drugs: atrial ﬁbrillation with preserved AV node conduction;
AF-abl, atrial ﬁbrillation group with ablated AV node.
M. Gasparini et al. v84intention-to-treatanalysis between the two modes (because of high
numbers of dropouts), HF patients who completed the study
improved in terms of functional status
26 with BVP. These effects
were maintained after 1 year for most patients.
27
Two other prospective studies investigated the effects of pacing
mode in the management of AF with rapid ventricular rates follow-
ing AVJ ablation. The OPSITE trial
28 showed that ‘rate control’
achieved following AVJ ablation signiﬁcantly improved symptoms
and functional status with no difference between the pacing mod-
alities, whether LV or RV, but in a population with much better LV
function. The PAVE
29 trial further conﬁrmed the beneﬁts of the
‘ablate and pace’ approach using different pacing modes. The
latter study observed a greater beneﬁt of the BVP mode in patients
with depressed LVEF ( 45%) and/or in NYHA functional class III.
Further observational studies have investigated the acute and
short-term effects of AVJ ablation in HF patients with AF treated
with CRT and have demonstrated an increase in global LV function,
a reduction of mitral regurgitation, and an increase in exercise
capacity;
30–32 others have conﬁrmed the chronic effects of CRT
in this patient subgroup, reporting improvements in NYHA class,
exercise capacity, and global LV function.
18,26,27,33,34 It is important
to stress that these beneﬁts appear to be conﬁned to AF patients
with previous AVJ ablation or spontaneous low-rate AF.
One large observational prospective investigation
18 speciﬁcally
evaluated the effects of AVJ ablation on CRT delivery using a pre-
deﬁned protocol. This study showed that only those AF patients
who underwent AVJ ablation (and thus approaching 100% effective
BVP) showed signiﬁcant improvements in LVEF, LVESV, and exer-
cise capacity. Furthermore, a signiﬁcantly higher proportion of
responders (response deﬁned as a  10% reduction in LVESV)
were observed in the AVJ ablation group (68%) compared with
the non-ablated group (18%) at 12 months. As later observed by
the same groups in a more extensive observational multicentre
study, CRT combined with AVJ ablation conferred a signiﬁcant
reduction of deaths for any cause compared with CRT alone, par-
ticularly by reducing deaths for progressive HF.
Taken together, based on current observational data on AF
populations treated with CRT, the beneﬁts of AVJ ablation in
allowing appropriate CRT delivery seem to outweigh the risks
associated with creating pacemaker dependency. The peculiarity
of CRT devices (using an RV and an LV pacing leads) should, theor-
etically, at least reduce the risks of pacemaker dependency related
to lead fractures or malfunction. Nonetheless, the fear of pace-
maker dependency remains a limiting aspect for the wider diffusion
of AVJ ablation.
The need for randomized
controlled clinical trials
Further studies are of course needed
10 to investigate the extensive
beneﬁts of adding AVJ ablation to CRT in HF patients with AF fol-
lowing a prospective, randomized, multicentre design. The
AVERT-AF
35 (Atrio-Ventricular Junction Ablation Followed by
Resynchronization Therapy in patients with CHF and AF) and
the An-Art study
36 (AV node ablation in CRT) are both concerned
with establishing whether AVJ ablation coupled with BVP may
signiﬁcantly improve functional capacity compared with pharmaco-
logical therapy in HF patients with permanent AF and depressed
EF. It should be stated that such studies aiming to assess the
effects of CRT according to soft/subjective endpoints may add
little to the current recommendations. There is a great need to
design RCTs with strong endpoints, even though such designs
may be difﬁcult to implement for ethical and ﬁnancial reasons.
A reasonable and ‘up-dated’ approach to investigate the effects
of CRT in this group involves using device-based surrogates of
major clinical events. Device-based remote continuous patient
monitoring may provide information on a daily basis of the
patients’ functional and clinical status, before the onset of an
overt clinical event becomes manifest.
37,38 But before these par-
ameters may be validated as surrogates for strong endpoints of
major cardiovascular events, better deﬁnition of their accuracy is
needed.
Conclusions
Atrial ﬁbrillation and other atrial rhythm disturbances in patients
with HF may have an important negative impact on the clinical
beneﬁt conveyed by CRT, if these are not appropriately
managed. Careful overall evaluation is mandatory to deﬁne pre-
cisely the AT/AF burden in order to articulate tailored diagnostic
and therapeutic strategies. On the basis of recent observational
data, in patients presenting intermediate or elevated AT/AF
burden, AVJ ablation may represent a fundamental tool to
achieve full CRT delivery and, thus, confer marked improve-
ments in global cardiac function, and, further, in survival. More
studies are necessary to further support the recourse to AVJ
ablation in this situation. Efforts should also be dedicated
towards establishing tailored treatment approaches to ade-
quately manage different atrial rhythm issues in HF patients
treated with CRT.
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